These results suggest that, in contrast to previous reports, sirolimus is sufficiently absorbed and, thus, may be an effective mTOR inhibitor for cancer therapy.59 Currently, phase 1 studies are evaluating oral sirolimus for the treatment of patients with human immunodeficiency virus-related Kaposi sarcoma60 and in combination with bevacizumab for the treatment of advanced solid tumors.61 Finally, a phase 1 study is assessing nanoparticle albumin-bound-rapamycin (ABI-009) in patients with advanced solid tumors, including sarcoma.62, 63. The gene discussed is MTOR; the disease is sarcoma.